SAN DIEGO, Aug. 6, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to evaluate the clinical utility and cost effectiveness of using Biocept’s Target Selector™ testing in patients diagnosed with non-small cell lung cancer (NSCLC). As part of the agreement, the Company’s liquid biopsy testing will be used to profile patients who have been diagnosed with NSCLC and/or have progressed on EGFR targeted therapy. Key objectives of the collaboration are to evaluate improvements in the molecular profiling rate of advanced NSCLC patients and the reduction of the overall cost of patient care.
“We are pleased to enter into this important collaboration, and believe that this initiative will help demonstrate the critical role that our Target Selector™ platform can fulfill in order to ensure that patients are given the option of a targeted therapy,” said Biocept’s President and Chief Executive Officer Michael Nall. “We remain committed to expanding our relationships with both managed care organizations as well as integrated healthcare delivery networks. Agreements such as this are helping us build upon the body of evidence supporting our proprietary liquid biopsy platform and its ability to help physicians rapidly obtain the actionable molecular information they need to improve patient outcomes.”
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit www.biocept.com.